<DOC>
	<DOC>NCT00382408</DOC>
	<brief_summary>This is a multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of oral DR-5001 in reducing the attack rate of febrile acute respiratory disease caused by type-4 and type-7 adenovirus as well as determine its immunogenicity.</brief_summary>
	<brief_title>A Clinical Trial to Evaluate the Safety, Efficacy, and Immunogenicity of DR-5001</brief_title>
	<detailed_description>The study will be conducted at two sites and will include a minimum of 4 visits. The overall study duration for participants will be approximately 8 weeks. Study participants will undergo acute respiratory disease evaluation that will include a throat swab and a blood draw. Each participant will also be contacted in six months for follow-up information.</detailed_description>
	<mesh_term>Respiratory Tract Diseases</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Military recruit in training Male or female; if female, must be of nonchildbearing potential or with a documented negative pregnancy test &lt;/= 72 hours prior to study medication administration and agree not to become pregnant Female nursing an infant or planning on nursing during the study Immunosuppressed for any reason, including past (within last 6 months) or current treatment with immunosuppressive therapy Known allergy to any component of the vaccines and/or placebo tablets Immunocompromised sexual partner or immunocompromised individuals in home</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Acute respiratory disease prevention</keyword>
	<keyword>Adenovirus</keyword>
</DOC>